Breaking News, Collaborations & Alliances

Enteris Completes Phase 1 Trial of Optimized Peptelligence Oral Leuprolide

Data indicates that the formulation delivers comparable or greater drug levels than subcutaneous or depot injection.

Author Image

By: Charlie Sternberg

Associate Editor

Enteris BioPharma Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation, has successfully completed a Phase 1 clinical trial investigating its optimized Peptelligence oral tablet formulation of leuprolide.    Data from the 22-patient study indicate that the optimized Peptelligence oral formulation is able to safely deliver a higher dose of leuprolide that enables blood concentrat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters